Objectives

The study’s goal is to examine the efficacy of various newer anti-diabetic drug combinations that include SGLT2 inhibitors (dapagliflozin), DPP-4 inhibitors (sitagliptin and vildagliptin) and metformin.

Materials and Methods

Patients with diabetes who had blood glucose levels that were managed (as per the established guidelines), as indicated by Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS), met the inclusion criteria for this study. Only a person’s medical history, medicines and glycemic control are taken consideration in this study. A sample size of 90 samples was included in the study and equally divided among three treatment groups, each of which received a certain treatment option. Each group is once again examined based on gender and the age ranges of 30 to 50 and 51 to 70 years.

Results and Discussion

Total 90 samples are considered in the study and divided into 3 group consist of 30 sample size Visit 1 is significant than Visit 2 and Visit 3 and Visit 2 is significant than Visit 3 (p value≤.000). In comparison to the other group, Group 1 achieved a better control of FBS and PPBS levels from Visit 1 to Visit 3, followed by the pharmacological therapy of Dapagliflozin and Sitagliptin.

Conclusion

The current study establishes for the first time that dapagliflozin, when used in combination with sitagliptin, vildagliptin and metformin, has comparable advantages for improving blood glucose control. When choosing a medicine combination to be used as the first line of treatment for people with type 2 diabetes, it is crucial.